References

S-109

1. Lan T, Chang L, Rahmathullah MN, et al. Comparative efficacy of interventional therapies for early-stage hepatocellular carcinoma: a PRISMA-compliant systemic review and network meta-analysis. *Med (Baltimore* 2016;95(15):e3185.
2. Varghese J, Kedarisetty C, Venkataraman J, et al. Combination of TACE and sorafenib improves outcomes of BCLC stages B/C of hepatocellular carcinoma: a single centre experience. *Ann Hepatol.* 2017;16(2):247-254.
3. Kim J, Sinn D, Shin S, et al. The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. *Clin Mole Hepatol.* 2017;23:42-50.
4. Nigri G, Petrucciani N, Debs T, et al. Treatment options for PNET liver metastases: a systematic review. *World J Surg Oncol.* 2018;16(1):N.PAG.
5. National Cancer Institute, Surveillance Epidemiolgoy and End Results Program. Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer. n.d.; https://seer.cancer.gov/statfacts/html/livibd.html. Accessed April 12, 2021.
6. Bush DA, Smith JC, Slater JD, et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. *Int J Radiat Oncol Biol Phys*. 2016;95(1):477-482.
7. Biederman DM, Titano JJ, Korff RA, et al. Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma. *J Vasc Interv Radiol.* 2018;29(1):30-37 e32.
8. Si T, Chen Y, Ma D, et al. Preoperative transarterial chemoembolization for resectable hepatocellular carcinoma in Asia area: a meta-analysis of random controlled trials. Scand J Gastroenterol. Dec 2016;51(12):1512-1519. PMID 27598831.
9. Yeh ML, Huang CI, Huang CF, et al. Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma. Kaohsiung J Med Sci. Feb 2015;31(2):77-82. PMID 25645985.
10. Liao M, Zhu Z, Wang H, et al. Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis. *Scand J Gastroenterol.* 2017;52(6- 7):624-634.

11. Liu H, Wang ZG, Fu SY, et al. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria. Br J Surg. 2016;103(4):348-356.
12. Ako S, Nakamura S, Nouso K, et al. Transcatheter arterial chemoembolization to reduce size of hepatocellular carcinoma before radiofrequency ablation. *Acta Med Okayama*. 2018;72(1):47-52.
13. Haochen W, Jian W, Li S, et al. Transarterial chemoembolization plus multi-imaging-guided radiofrequency ablation for elimination of hepatocellular carcinoma nodules measuring 3.1 to 5.0 cm: a single-center study. *J Int Med Res*. 2018:300060518768420.
14. Bholee AK, Peng K, Zhou Z, et al. Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. *Clin Transl Oncol.* 2017;19(7):844-852.
15. Li L, Tian J, Liu P, et al. Transarterial chemoembolization combination therapy vs monotherapy in unresectable hepatocellular carcinoma: a meta-analysis. 2016;2016(3):301-310.
16. Wang X, Hu Y, Ren M, et al. Efficacy and safety of radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinomas compared with radiofrequency ablation alone: a time-to-event meta-analysis. Korean J Radiol. Jan-Feb 2016;17(1):93-102. PMID 26798221.
17. Yi Y, Zhang Y, Wei Q, et al. Radiofrequency ablation or microwave ablation combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma by comparing with radiofrequency ablation alone. Chin J Cancer Res. Feb 2014;26(1):112-118. PMID 24653633.
18. Organ Procurement and Transplantation Network (OPTN). Organ Distribution: Allocation of Livers. April 04, 2021. http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy_8.pdf. Accessed April 12, 2021.
19. Organ Procurement and Transplantation Network (OPTN). OPTN Policies. 2021; https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf#nameddest=Policy_09. Accessed April 12, 2021.
20. Si T, Chen Y, Ma D, et al. Transarterial chemoembolization prior to liver transplantation for patients with hepatocellular carcinoma: A meta-analysis. *J Gastroenterol Hepatol.* 2017;32(7):1286-1294.
21. Gabr A, Abouchaleh N, Ali R, et al. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. *Eur J Radiol.* 2017;93:100- 106.
22. Liu Y, Li Y, Gao F, et al. Comparison of transcatheter arterial chemoembolization-radiofrequency ablation and transcatheter arterial

chemoembolization alone for advanced hepatocellular carcinoma with macrovascular invasion using propensity score analysis: A retrospective cohort study. *J Oncol.* 2020:1-12
23. Hayes, Inc. Hayes Health Technology Assessment. *Radioactive yttrium-90 microspheres for the treatment of primary unresectable liver cancer for downstaging or as a bridge to transplantation or surgery.* Lansdale, PA. Hayes, Inc.; 04/09/2021.
24. InterQual® Level of Care Criteria 2019. Acute Care Adult. Change Healthcare, LLC.
25. Shen PC, Chang WC, Lo CH, et al. Comparison of stereotactic body radiation therapy and transarterial chemoembolization for unresectable medium-sized hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2019;105(2):307-318.
26. Gui CH, Baey S, D'cruz RT, et al. Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma - A meta-analysis. *Eur J Surg Oncol.* 2020;46(5):763-771.
27. Seidensticker R, Seidensticker M, Doegen K, et al. Extensive use of interventional therapies improves survival in unresectable or recurrent intrahepatic cholangiocarcinoma. *Gastroenterol Res Pract.* 2016;2016:8732521.
28. Rowcroft A, Loveday BPT, Thomson BNJ, et al. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. *HPB (Oxford).* 2020;22(4): 497-505.
29. Swierz MJ, Storman D, Riemsma RP, et al. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases. *Cochrane Database Syst Rev*. 2020;3:CD009498.
30. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Hepatobiliary Cancers, Version 1.2021. Updated March 05, 2021. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed April 12, 2021.
31. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Uveal Melanoma, Version 1.2021. Updated October 20, 2020. https://www.nccn.org/professionals/physician_gls/pdf/uveal.pdf. Accessed April 12, 2021.
32. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Neuroendocrine and Adrenal Tumors, Version 2.2020. Updated July 24, 2020. https://www.nccn.org/professionals/physician gls/pdf/neuroendocrine.pdf. Accessed April 12, 2021.

33. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon Cancer, Version 2.2021. Updated May 6, 2020. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed April 12, 2021.
34. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Breast Cancer, Version 3.2021. Updated March 29, 2021. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed April12, 2021.